Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2004

View Archived Issues

New class of ketolide antibacterial agents developed at Kosan

RBx-8700 shows potent activity against respiratory tract pathogens and resistant enterococci

Davanat progress updated

Vertex initiates phase Ib study for VX-950

Phase Ib study to evaluate KOS-953 plus Velcade in myeloma

Bioniche Life Sciences plans phase III study for Urocidin

Transition Therapeutics to acquire interest in Ellipsis Neurotherapeutics

New clinical trial planned for Vytorin in ACS patients

Ligand restructures Ontak agreement with Lilly

Use of diazoxide for treatment of ischemia retinae claimed in CNRS patent

Roche claims 5-HT6 receptor modulators

New mGluR5 antagonists presented by Roche

GSK-3 inhibitors described by Pfizer researchers

Factor Xa inhibitors claimed by Bristol-Myers Squibb

Pramipexole for reducing excessive food intake

Ligand and Royalty Pharma amend royalty agreement for SERM products

Analgesic effects of nonpeptide somatostatin agonist

Actelion stops VERITAS study of tezosentan

Amrad and LICR sign collaboration agreement on VEGF-B

CaMk-II inhibitor shows efficacy in experimental model of cerebral ischemia

Novel ketolide antibiotic more potent than telithromycin

PharmaFrontiers closes acquisition of the multiple sclerosis focused Opexa Pharmaceuticals

DNA topoisomease IV inhibitor effective against S. aureus

Discontinuation of phase II pamirosin trial for BPH

Enrollment completed in three phase II trials of NS-2330

NS-2359 completes phase II study in ADHD

Icofungipen shows promise in the treatment of oropharyngeal candidiasis

NEP/ECE inhibitor SLV-306 reduces proteinuria and urinary albumin excretion in diabetic neuropathy

Acute renal injury in anti-GBM glomerulonephritis acts via a JNK-dependent mechanism

CCR1 blockade reverses chronic allograft nephropathy

LR-103 effective in bone parameter normalization in secondary hyperparathyroidism transgenic model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...